Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond

Giulio Rosati, Andrea Idili, Claudio Parolo, Celia Fuentes-Chust, Enric Calucho, Liming Hu, Cecilia De Carvalho Castro Silva, Lourdes Rivas, Emily P. Nguyen, José Francisco Bergua Canudo, Ruslan Álvarez Diduk, José Muñoz, Christophe Junot, Oriol Penon, Dominique Monferrer, Emmanuel Delamarche, Arben Merkoçi

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

48 Cites (Scopus)

Resum

The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.
Idioma originalAnglès
Pàgines (de-a)17137-17149
Nombre de pàgines13
RevistaACS Nano
Volum15
Número11
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Nanodiagnostics to face SARS-CoV-2 and future pandemics : from an idea to the market and beyond'. Junts formen un fingerprint únic.

Com citar-ho